Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542499 · ClinicalTrials.gov registry record · Phase 3
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 507
- Enrollment target
NCT04542499 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 507 participants.
The verdict
NCT04542499, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 507 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
Interventions
- DRUG Placebo
- DRUG Tavapadon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542499
The ClinicalTrials.gov registry entry for NCT04542499 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04542499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542499 about?
NCT04542499 is a clinical study titled "Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)". The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
What is the current status of trial NCT04542499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 507 participants. The study started on 2020-09-23. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT04542499?
The interventions under investigation include: Placebo (DRUG), Tavapadon (DRUG).
Who is sponsoring clinical trial NCT04542499?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.